Literature DB >> 12241110

Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.

Keith A Lerro1, Jill Lacy.   

Abstract

We report the case of a 72-year-old woman with primary CNS lymphoma of the mid-brain and pons who had a complete response to oral temozolomide chemotherapy. She initially presented in early 2001 with several weeks of progressive memory loss and unresponsiveness. Because of her age and impaired renal function, she was a poor candidate for whole-brain radiotherapy or systemic high-dose methotrexate. After treatment with two cycles of temozolomide, restaging MRI revealed no evidence of disease. Her mental status improved significantly over this time. Temozolomide may represent a promising new drug for the treatment of primary CNS lymphoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12241110     DOI: 10.1023/a:1019682400415

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

Review 1.  Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL).

Authors:  D F Nelson
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

2.  PCV salvage chemotherapy for recurrent primary CNS lymphoma.

Authors:  U Herrlinger; W Brugger; M Bamberg; W Küker; J Dichgans; M Weller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

3.  Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.

Authors:  M Reni; A J Ferreri; C Landoni; E Villa
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

4.  Non-Hodgkin's lymphoma time trends: United States and international data.

Authors:  S S Devesa; T Fears
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

5.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Authors:  C Soussain; F Suzan; K Hoang-Xuan; N Cassoux; V Levy; N Azar; C Belanger; E Achour; V Ribrag; S Gerber; J Y Delattre; V Leblond
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

6.  Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group.

Authors:  T R Coté; A Manns; C R Hardy; F J Yellin; P Hartge
Journal:  J Natl Cancer Inst       Date:  1996-05-15       Impact factor: 13.506

7.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

8.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

9.  Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

Authors:  C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

10.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  3 in total

1.  O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.

Authors:  Jun-Ichi Adachi; Kazuhiko Mishima; Kenji Wakiya; Tomonari Suzuki; Kohei Fukuoka; Takaaki Yanagisawa; Masao Matsutani; Atsushi Sasaki; Ryo Nishikawa
Journal:  J Neurooncol       Date:  2011-10-04       Impact factor: 4.130

2.  Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.

Authors:  Antonio M P Omuro; Luc Taillandier; Olivier Chinot; Charlotte Carnin; Maryline Barrie; Khe Hoang-Xuan
Journal:  J Neurooncol       Date:  2007-09-21       Impact factor: 4.130

3.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.